With Pres. Biden ready to pull the trigger on booster shots as early as next week, vaccine experts advising the UFDA huddled to debate the merits of third doses of the Pfizer vaccine for people 16 and older.
Health experts are divided as the FDA panel convenes to review Pfizer's recommendation that people 16 and over receive a third shot of the vaccine.With President Joe Biden ready to pull the trigger on booster shots as early as next week, vaccine experts advising the U.S. Food and Drug Administration huddled Friday to debate the merits of third doses of the Pfizer vaccine for people 16 and older.
The debate has become unusually charged, in part because of White House involvement. Biden said he would only act on rolling out boosters if the FDA and Centers for Disease Control and Prevention agreed. But his public pronouncement that the rollout would begin as early as Monday suggested the decision was a foregone conclusion, leading to accusations by some scientists that the Biden administration was pressuring independent regulators.
The next step would be a review next week by the CDC to determine who exactly should get a booster. After that CDC recommendation is made, booster shots would be available through any of the nation's 40,000 pharmacies, doctors offices and other sites already offering the Pfizer vaccine. The CDC has said vaccines still offer extraordinary protection against hospitalization and death, with more than 90% of patients hospitalized with COVID-19 being unvaccinated. At Friday's FDA briefing, a CDC official said vaccine effectiveness against hospitalization in adults age 75 and older remained at about 88% through July.A new Israeli study published in the New England Journal of Medicine found 11.3-fold lower rates of infection and 19.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
FDA panel is first key test for Biden COVID-19 booster planGovernment advisers are debating whether to recommend extra doses of the Pfizer vaccine, a key step toward the Biden administration's plan to dispense COVID-19 booster shots. Scientists have been divided over the need for boosters and who should get them.
Lire la suite »
What to expect as FDA advisory panel debates Pfizer COVID booster shotsThe FDA's independent advisory committee is convening to review data submitted by Pfizer and discuss whether a booster dose is safe enough for widespread use and whether it's necessary and effective at improving protection levels against COVID-19.
Lire la suite »
FDA Panel Weighs Covid-19 Booster Shots as Health Officials Debate NeedThe Biden administration’s push to introduce widespread vaccine boosters faces a test as a Food and Drug Administration advisory panel meets to weigh evidence on the extra shots, a topic that has divided federal health officials.
Lire la suite »
Delta-8 Cannabis Products Can Cause Scary Health Effects, the CDC and FDA WarnThey're largely unregulated and poorly labeled.
Lire la suite »
FDA Questions Need For Pfizer Covid-19 Booster Shot Ahead Of Vote FridayScientists at the FDA said Pfizer’s Covid-19 vaccine seems to last long enough that a booster shot may not add much protection
Lire la suite »